Tumor specific monoclonal antibodies

Details Tumor specific monoclonal antibodies Tumor specific monoclonal antibodies

1989-01-25

1992-04-21

Doll, John

Chemistry: molecular biology and microbiology

Treatment of micro-organisms or enzymes with electrical or...

Modification of viruses

C12N 1502

Patent

active

051067382

ABSTRACT:
A method for producing a human B-lymphocyte that is able to grow in cell culture and produces human monoclonal antibodies having binding specificity for tumor-associated antigens by exposing a human B-lymphocyte to a tumor cell antigen in a vaccine containing viable human tumor cells that have been made non-tumorigenic, and immortalizing the exposed B-lymphocyte by exposing to a transforming agent for sufficient time to transform the B-lymphocyte.

REFERENCES:
patent: 4661586 (1987-04-01), Levy et al.
patent: 4828991 (1989-05-01), Hanna et al.
Kozbor, D. et al., Proc. Natl. Acad. Sci., 79:6651-6655, 1982.
Takayama, T., Nihon Univ. J. Med., 26(5) Abstract, 1984.
Boyd, J. E. et al., Trends Biotechnol., 2(3):70-77, 1984.
Roome, A. J. et al., Rev. Can. Biol. Exp., 43(1):35-55, 1984
Toffaletti, D. L. et al., J. of Immunol., 130(6):2982-2986 (1983).
O'Donnell, R. W. et al., Som. Cell. Mol. Gen, 10(2):195-204, 1984.

Affiliated with

Also associated with

Rating

Tumor specific monoclonal antibodies does not yet have a rating. At this time, there are no reviews or comments for this patent.

If you have personal experience with Tumor specific monoclonal antibodies, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Tumor specific monoclonal antibodies will most certainly appreciate the feedback.

Rate now

Comments { 0 }

Profile ID: LFUS-PAI-O-1585486